PepGen Stock News

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.

BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review.

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myoto...

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2026, and recent corporate highlights. "We made encour...